Cystic Fibrosis Clinical Trials in Kansas City, Kansas

11 studies are recruiting for cystic fibrosis in Kansas City, Kansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sinus Disease in Young Children With Cystic Fibrosis

   This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: ch…

   Stage

   Not phased

   Ages

   2 to 8

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   6 in total

   Run by

   University of California, Los Angeles

   See if you can join NCT06191640 on ClinicalTrials.gov

2. Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

   This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).

   Stage

   Not phased

   Ages

   Up to 10

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   35 in total

   Run by

   Sonya Heltshe

   See if you can join NCT04509050 on ClinicalTrials.gov

3. Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

   The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs me…

   Stage

   Phase 4

   Ages

   6 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   60 in total

   Run by

   Chris Goss

   See if you can join NCT05548283 on ClinicalTrials.gov

4. Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

   The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

   Stage

   Phase 1

   Ages

   3 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Run by

   Mario Castro, MD, MPH

   See if you can join NCT04624490 on ClinicalTrials.gov

5. Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

   The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT04530383 on ClinicalTrials.gov

6. Health Outcomes of Parents With Cystic Fibrosis-Aim 2

   The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the im…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   18 in total

   Run by

   University of Pittsburgh

   See if you can join NCT06296394 on ClinicalTrials.gov

7. Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

   RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor …

   Stage

   Not phased

   Ages

   6 and older

   Site

   Kansas University Medical Center, Kansas City, Kansas

   Locations

   18 in total

   Run by

   Boston Children's Hospital

   See if you can join NCT06683092 on ClinicalTrials.gov

8. A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

   The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to in…

   Stage

   Not phased

   Ages

   12 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   68 in total

   Run by

   Nicole Hamblett

   See if you can join NCT06504589 on ClinicalTrials.gov

9. Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

   The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants wil…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT06364176 on ClinicalTrials.gov

10. A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

    This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    University of Kansas Medical Center, Kansas City, Kansas

    Locations

    4 in total

    Run by

    Spirovant Sciences, Inc.

    See if you can join NCT06526923 on ClinicalTrials.gov

11. BEGIN Novel ImagiNG Biomarkers

    To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).

    Stage

    Phase 4

    Ages

    6 to 8

    Site

    University of Kansas Medical Center, Kansas City, Kansas

    Locations

    3 in total

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT05517655 on ClinicalTrials.gov